


PHARMACEUTICAL 2017

SCYNEXIS INC Rank 163 of 313







PHARMACEUTICAL 2017

SCYNEXIS INC Rank 163 of 313



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 209% points. The greatest weakness of SCYNEXIS INC is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -197%, being 220% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	59,327
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,717
Liabilities, Non-Current	14,252
Other Assets	465
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	7,004
Other Net Income	-2,172
Property and Equipment	0
Research and Development	20,076
Revenues	257
Selling, General and Administrative Expense	7,998

Output Variable	Value in 1000 USD
Assets	59,792
Liabilities	24,973
Expenses	28,074
Stockholders Equity	34,819
Net Income	-29,989
Comprehensive Net Income	-29,989
Economic Capital Ratio	-197%